ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition

p53 centrosomal localization diagnoses ataxia-telangiectasia homozygotes and heterozygotes

(2013) Andrea Prodosmo et al.   JOURNAL OF CLINICAL INVESTIGATION

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib

(2012) Anneleen Daemen et al.   BREAST CANCER RESEARCH AND TREATMENT

Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro

(2012) A. G. Patel et al.   CLINICAL CANCER RESEARCH

Role of PARP Inhibitors in Cancer Biology and Therapy

(2012) D. Davar et al.   CURRENT MEDICINAL CHEMISTRY

The DNA damage response and cancer therapy

(2012) Christopher J. Lord et al.   NATURE

Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor

(2011) X. Liu et al.   CLINICAL CANCER RESEARCH

Beyond ATM: The protein kinase landscape of the DNA damage response

(2011) Ariel Bensimon et al.   FEBS LETTERS

Inherited Mutations in Breast Cancer Genes—Risk and Response

(2011) Andrew Y. Shuen et al.   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

(2011) Karen A Gelmon et al.   LANCET ONCOLOGY

Stumbling Blocks on the Path to Personalized Medicine in Breast Cancer: The Case of PARP Inhibitors for BRCA1/2 -Associated Cancers

(2011) Judith Balmaña et al.   Cancer Discovery

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo

(2010) V. J. Weston et al.   BLOOD

Multiple roles of ATM in monitoring and maintaining DNA integrity

(2010) Frederick A. Derheimer et al.   FEBS LETTERS

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors

(2010) C. T. Williamson et al.   MOLECULAR CANCER THERAPEUTICS

Synthetic lethal approaches to breast cancer therapy

(2010) Farah L. Rehman et al.   Nature Reviews Clinical Oncology

The combined status of ATM and p53 link tumor development with therapeutic response

(2009) H. Jiang et al.   GENES & DEVELOPMENT

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene Discovery

(2009) Jessica Kao et al.   PLoS One

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

(2008) Nicholas C Turner et al.   EMBO JOURNAL

Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer

(2008) Martin F. Lavin   NATURE REVIEWS MOLECULAR CELL BIOLOGY